Know Cancer’s Next Move: Using ctDNA to guide treatment decisions in patients with GI Cancer

March 27, 2023

This webinar will explore the expanding role of circulating tumor DNA (ctDNA) for assessing molecular residual disease (MRD) and monitoring treatment response in patients with colorectal cancer.

Know Cancer’s Next Move: Using ctDNA to guide treatment decisions in patients with GI Cancer

Using ctDNA to help inform the management of patients with low-risk colorectal cancer (with subtitles)

Using ctDNA to help inform the management of patients with low-risk colorectal cancer

Using ctDNA to help inform the management of patients with locally advanced rectal cancer (with subtitles)

Using ctDNA to help inform the management of patients with locally advanced rectal cancer

The expanding role of ctDNA in colorectal cancer to optimize patient management

The expanding role of ctDNA in colorectal cancer to optimize patient management (with subtitles)

How ctDNA can transform interventional trial design for GI cancers

Seeing the Forest Through the Trees: How tumor informed MRD testing can illuminate the treatment pathway in GI cancer

Seeing the Forest Through the Trees: Using tumor-informed MRD testing to illuminate the treatment pathway in GI cancer

Personalized ctDNA testing to help guide treatment decisions in breast cancer

Webinar: Breast Cancer 2023 Data & Post-SABCS Summary

Panel Discussion: How ctDNA Testing is Informing the Management of Patients With GI Cancer - Direct

Locate and Track: ctDNA Monitoring in NSCLC with Signatera

Keith's Story

ctDNA monitoring to optimize immunotherapy treatment decisions

Detect. Monitor. Optimize: Signatera’s Impact on Breast Cancer Management

Signatera Ordering

Post-ASCO Summary: ctDNA as a patient selection and early efficacy marker in drug development

Powering Precision: The essential role of ctDNA testing for MRD assessment in GI malignancies - Direct

3988 - Natera - Tampa - Breast Cancer V6e (1)